Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Uterine Neoplasms 1Endometrial Neoplasms 1Carcinoma 1

Interventions

pembrolizumab 1251Specimen Handling 867Carboplatin 816Magnetic Resonance Spectroscopy 803Cyclophosphamide 794Cisplatin 715Nivolumab 646Paclitaxel 623Radiotherapy 564Gemcitabine 562Biopsy 529Bevacizumab 468Dexamethasone 433fludarabine 404Docetaxel 370venetoclax 365Oxaliplatin 362Fluorouracil 352Capecitabine 350atezolizumab 341Rituximab 326durvalumab 326Doxorubicin 313Radiosurgery 305Pemetrexed 302Drug Therapy 294Standard of Care 292Ipilimumab 289Etoposide 279Radiation 277

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × VMBP protocol × 1 year × Clear all
NCT05559879 2026-04-15

Cabozantinib and Dostarlimab in Recurrent Gynecologic Carcinosarcoma

University of Alabama at Birmingham

Phase 1/2 Recruiting
37 enrolled
Gynecologic

Carcinoma, Uterine Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡